Printed From BioPortfolio.com
Atriva receives an additional seed financing to develop its influenza therapeutic to clinical stage
03:00 EDT 22 Sep 2017 | Bionity
The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriv...
Original Article: Atriva receives an additional seed financing to develop its influenza therapeutic to clinical stage
